Company: IMRX
Filing Date: 2025-08-13
Form Type: 10-Q
Source: 0001790340-25-000104
Chunk: 369

Company: Immuneering Corp
Filing Date: 2025-08-13
Form: 10-Q
Item: Part I, Item 8
Chunk 369
---
3TotalAssets:Cash equivalentsMoney market$35,865,754 $— $— $35,865,754 Total cash equivalents$35,865,754 $— $— $35,865,754 

Note 5 – Property and Equipment, net

Property and equipment, net consisted of the following:June 30,2025December 31,2024Computer equipment$581,839 $570,778 Furniture and fixtures98,628 98,628 Lab equipment1,236,233 1,236,233 Leasehold improvements298,941 298,941 Total2,215,641 2,204,580 Accumulated depreciation and amortization(1,251,503)(1,081,715)Property and equipment, net$964,138 $1,122,865 Depreciation and amortization expense totaled $84,527 and $90,533 for the three months ended June 30, 2025 and 2024, respectively. Depreciation and amortization expense totaled $169,788 and $180,742 for the six months ended June 30, 2025 and 2024, respectively.

Note 6 – Accrued Expenses

Accrued expenses consisted of the following:June 30,2025December 31,2024Accrued professional services$496,447 $193,646 Accrued employee expenses1,827,266 3,583,649 Accrued research and development expenses2,081,175 1,106,872 Accrued other expenses110,072 88,962 Total$4,514,960 $4,973,129 

Note 7 - Common Stock

The Company had 200,000,000 authorized shares of Class A common stock, $0.001 par value per share as of June 30, 2025 and December 31, 2024 of which 35,987,306 and 31,050,448 were issued and outstanding, respectively. The holders of Class A common stock are entitled one vote for each share of common stock. Dividends may be paid when, and if, declared by the Board of Directors, subject to the limitations, powers and preferences granted to the Preferred Stockholders and on a proportionate basis with holders of Class B common stock.

16

The Company had 20,000,000